Contact:

604-688-0221 ext: 524

Follow:

Bacchus Barua

Associate Director, Health Policy Studies, Fraser Institute

Bacchus Barua is Associate Director of the Fraser Institute’s Centre for Health Policy Studies. He completed his BA (Honours) in Economics at the University of Delhi (Ramjas College) and received an MA in Economics from Simon Fraser University. Bacchus has conducted research on a range of key health care topics including hospital performance, access to new pharmaceuticals, the impact of aging on health care expenditures, and international comparisons of health care systems. He also designed the Provincial Healthcare Index (2013) and is the lead author of The Effect of Wait Times on Mortality in Canada, and Waiting Your Turn: Wait Times for Health Care in Canada (2010–2014).

Recent Research by Bacchus Barua

— Mar 28, 2019
Printer-friendly version
The Private Cost of Public Queues for Medically Necessary Care, 2019

The Private Cost of Public Queues for Medically Necessary Care, 2019 finds that Canada’s long wait times for medically necessary treatments cost Canadians $2.1 billion—or $1,924 per patient—in lost wages and time last year. Including the value of lost time outside the traditional work week—evenings and weekends—the estimated cost of waiting for medical care jumps to $6.3 billion. It’s estimated that more than one million Canadians waited for medically necessary treatment in 2018.

— Feb 5, 2019
Printer-friendly version
Health Care Reform Options for Alberta

Health Care Reform Options for Alberta finds that the Alberta government can enact major health-care reforms—without contravening the Canada Health Act—that would shorten wait times and improve patient care. For example, increasing the use of private clinics, creating a centralized surgical registry and pooling patient referrals, and allowing private, parallel financing and delivery of medically necessary services, none of which are explicitly prohibited by federal legislation.

— Jan 24, 2019
Printer-friendly version
Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective

Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective finds that the federal government’s plan to lower prescription drug prices through changes to the Patented Medicine Prices Review Board could impede access of new life-saving drugs for Canadian patients and even discourage innovation in the pharmaceutical sector.